|
|
| | moflomycin Basic information |
| Product Name: | moflomycin | | Synonyms: | moflomycin;F 860191;F860191;F-860191;5,12-Naphthacenedione, 7-[(2,6-dideoxy-2-iodo-α-L-mannopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxymethyl)-, (7S,9S)- (9CI) | | CAS: | 107430-03-5 | | MF: | C25H25IO10 | | MW: | 612.37 | | EINECS: | | | Product Categories: | | | Mol File: | 107430-03-5.mol |  |
| | moflomycin Chemical Properties |
| Boiling point | 786.1±60.0 °C(Predicted) | | density | 1.93±0.1 g/cm3(Predicted) | | pka | 7.90±0.60(Predicted) |
| | moflomycin Usage And Synthesis |
| Uses | Moflomycin (F 860191) is a compound with strong anti-leukemic activity and low mutagenicity. Moflomycin has an antiproliferative effect on the leukemic cell line HL60 in vitro (IC50=2.9 nM)[1]. Moflomycin enhances topoisomerase II-induced DNA breaks and free radical production[2]. | | References | [1] Andrivon W, et al. A new anthracycline with potent antileukemic activity exhibits reduced mutagenicity[J]. Mutation Research/Genetic Toxicology, 1995, 344(3-4): 135-140. DOI:10.1016/0165-1218(95)00052-6
[2] Andrivon W, et al. Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity. Leuk Res. 1996 Feb;20(2):119-26. DOI:10.1016/0145-2126(95)00155-7 |
| | moflomycin Preparation Products And Raw materials |
|